Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy - PubMed (original) (raw)
Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy
Ming-Jie Li et al. Mol Ther. 2005 Nov.
Free article
Abstract
Combinatorial therapies for the treatment of HIV-1 infection have proven to be effective in reducing patient viral loads and slowing the progression to AIDS. We have developed a series of RNA-based inhibitors for use in a gene therapy-based treatment for HIV-1 infection. The transcriptional units have been inserted into the backbone of a replication-defective lentiviral vector capable of transducing a wide array of cell types, including CD34+ hematopoietic progenitor cells. The combinatorial therapeutic RNA vector harbors a U6 Pol III promoter-driven short hairpin RNA (shRNA) targeting the rev and tat mRNAs of HIV-1, a U6 transcribed nucleolar-localizing TAR RNA decoy, and a VA1-derived Pol III cassette that expresses an anti-CCR5 ribozyme. Each of these therapeutic RNAs targets a different gene product and blocks HIV infection by a distinct mechanism. Our results demonstrate that the combinatorial vector suppresses HIV replication long term in a more-than-additive fashion relative to the single shRNA or double shRNA/ribozyme or decoy combinations. Our data demonstrate the validity and efficacy of a combinatorial RNA-based gene therapy for the treatment of HIV-1 infection.
Similar articles
- RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.
Li M, Li H, Rossi JJ. Li M, et al. Ann N Y Acad Sci. 2006 Oct;1082:172-9. doi: 10.1196/annals.1348.006. Ann N Y Acad Sci. 2006. PMID: 17145937 Review. - SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC, Cordelier P, Patel C, BouHamdan M, Johnson RP, Lisziewicz J, Pomerantz RJ, Strayer DS. Jayan GC, et al. Gene Ther. 2001 Jul;8(13):1033-42. doi: 10.1038/sj.gt.3301481. Gene Ther. 2001. PMID: 11438838 - Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.
Li MJ, Bauer G, Michienzi A, Yee JK, Lee NS, Kim J, Li S, Castanotto D, Zaia J, Rossi JJ. Li MJ, et al. Mol Ther. 2003 Aug;8(2):196-206. doi: 10.1016/s1525-0016(03)00165-5. Mol Ther. 2003. PMID: 12907142 - High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C, Irvine A, Wrighton C, Craig R, Dzierzak E. Fraisier C, et al. Gene Ther. 1998 Dec;5(12):1665-76. doi: 10.1038/sj.gt.3300780. Gene Ther. 1998. PMID: 10023446 - siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
Akkina R, Banerjea A, Bai J, Anderson J, Li MJ, Rossi J. Akkina R, et al. Anticancer Res. 2003 May-Jun;23(3A):1997-2005. Anticancer Res. 2003. PMID: 12894572 Review.
Cited by
- Optimal delivery of RNA interference by viral vectors for cancer therapy.
Wong B, Birtch R, Rezaei R, Jamieson T, Crupi MJF, Diallo JS, Ilkow CS. Wong B, et al. Mol Ther. 2023 Nov 1;31(11):3127-3145. doi: 10.1016/j.ymthe.2023.09.012. Epub 2023 Sep 20. Mol Ther. 2023. PMID: 37735876 Review. - MicroRNAs in T Cell-Immunotherapy.
Dosil SG, Rodríguez-Galán A, Sánchez-Madrid F, Fernández-Messina L. Dosil SG, et al. Int J Mol Sci. 2022 Dec 23;24(1):250. doi: 10.3390/ijms24010250. Int J Mol Sci. 2022. PMID: 36613706 Free PMC article. Review. - Development and classification of RNA aptamers for therapeutic purposes: an updated review with emphasis on cancer.
Razlansari M, Jafarinejad S, Rahdar A, Shirvaliloo M, Arshad R, Fathi-Karkan S, Mirinejad S, Sargazi S, Sheervalilou R, Ajalli N, Pandey S. Razlansari M, et al. Mol Cell Biochem. 2023 Jul;478(7):1573-1598. doi: 10.1007/s11010-022-04614-x. Epub 2022 Nov 24. Mol Cell Biochem. 2023. PMID: 36434145 Review. - Engineered Zinc Finger Protein Targeting 2LTR Inhibits HIV Integration in Hematopoietic Stem and Progenitor Cell-Derived Macrophages: In Vitro Study.
Chupradit K, Khamaikawin W, Sakkhachornphop S, Puaninta C, Torbett BE, Borwornpinyo S, Hongeng S, Wattanapanitch M, Tayapiwatana C. Chupradit K, et al. Int J Mol Sci. 2022 Feb 19;23(4):2331. doi: 10.3390/ijms23042331. Int J Mol Sci. 2022. PMID: 35216446 Free PMC article. - Lentivirus-mediated Conditional Gene Expression.
Rommereim L, Akhade AS, Germain RN, Fraser IDC, Subramanian N. Rommereim L, et al. Bio Protoc. 2021 Nov 5;11(21):e4205. doi: 10.21769/BioProtoc.4205. eCollection 2021 Nov 5. Bio Protoc. 2021. PMID: 34859120 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- AI057066/AI/NIAID NIH HHS/United States
- AI061839/AI/NIAID NIH HHS/United States
- AI29329/AI/NIAID NIH HHS/United States
- AI42552/AI/NIAID NIH HHS/United States
- AI50492/AI/NIAID NIH HHS/United States
- P30 AI054907/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical